We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
You may need to tell DVLA if you have cancer - if you do, download the correct form to let them know
Quarterly updates to the emergency presentations of cancer data by Public Health England.
Game-changing AI technology will be rolled out to all radiography departments in England in a matter of weeks – backed by £15.5 million in new Government funding.
You may need to tell DVLA if you have malignant melanoma - download the correct form if you need to let them know
You may need to tell DVLA if you have lung cancer - download the correct form if you need to let them know
Chief Medical Officer for England, Professor Chris Whitty's annual reports and lectures on medicine and public health.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
The epidemiology, symptoms, diagnosis and management of human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2).
How to classify and describe your business waste so you can know how to manage and dispose of it - what you need to do, List of Waste (LoW) codes, technical guidance.
Information on depleted uranium (DU) including what it is, its uses, health effects and protection from exposure.
This document explains the Prostate Cancer Risk Management Programme (PCRMP), PSA testing and evidence against a national screening programme.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
Advice for medical professionals to follow when assessing drivers with neurological disorders.
The estimates as recommended by Public Health England.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).